How to Standardize Audit Risks and Legal Exposure Management Across Global Markets

Context

Effective management of audit risks and legal exposures is paramount for pharmaceutical and biotech companies, particularly those involved with controlled substances. Compliance with multi-regulatory frameworks across the US, EU, and UK presents unique challenges that require a standardized approach. Regulatory Affairs (RA) professionals must navigate a web of regulations and guidelines to assure compliance while protecting the organization from potential legal ramifications.

Legal/Regulatory Basis

The regulations governing the handling of controlled substances fall under various jurisdictions, with key regulatory frameworks including:

• United States: The Drug Enforcement Administration (DEA) regulates controlled substances under the Controlled Substances Act (CSA). Compliance is enforced through 21 CFR Part 1300-1399, which delineates the scheduling, manufacturing, distribution, and disposal of controlled substances.
• European Union: The EU’s legal framework covering controlled substances is primarily governed by the European Medicines Agency (EMA) and includes regulations under Directive 2001/83/EC and Regulation (EC) No 726/2004, complemented by national laws from member states.
• United Kingdom: The Misuse of Drugs Act 1971 and its associated regulations regulate controlled substances in the UK, with enforcement by the Home Office and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

RA teams must be familiar with these legal underpinnings to ensure compliance with both local and international requirements.

Documentation

Documentation is a foundational pillar of compliance for controlled substances. The following are essential documents to maintain:

• Registration Documents: Ensure all facilities involved in the handling of controlled substances are properly registered with relevant authorities to avoid legal exposure.
• Controlled Substance Schedules: Maintain accurate and updated records of the controlled substances you handle and their respective schedules as defined by regulatory guidelines.
• Standard Operating Procedures (SOPs): Develop and regularly update SOPs that describe procedures for the handling, storage, and disposal of controlled substances.
• Audit Trails: Maintain comprehensive records of all transactions involving controlled substances, which would enable rapid response to audit requests or inspections.

Proper documentation not only ensures compliance but serves as evidence of a robust compliance framework in the event of regulatory audits.

Review/Approval Flow

The review and approval process for controlled substances differs significantly across jurisdictions. Below is a structured overview of the typical flow involving Regulatory Affairs:

1. Preliminary Assessment: Identify the need for controlled substance handling within your organization, including the type and schedule of the substance.
2. Agency Interaction: Engage with the regulatory authority early to clarify classification and compliance expectations. In the US, this may involve obtaining a DEA registration.
3. Submission Preparation: Assemble documentation and data files as required based on the classification, including CMC and clinical data pertinent to the controlled substance.
4. Filing Submission: Submit the required applications or variations. In the US, file with the FDA and DEA simultaneously if both regulations apply.
5. Agency Review: The agency will assess the submission; be ready to provide additional information or clarification as requested.
6. Approval and Compliance Monitoring: Upon approval, ensure continuous compliance with regulations and maintain up-to-date documentation.

The review process can lead to approval delays if documentation is inadequate or if the submission does not align with regulatory expectations.

Common Deficiencies

In the context of controlled substances, agencies commonly identify the following deficiencies during inspections or submissions:

• Incomplete Registration: Facilities not properly registered or individuals lacking necessary credentials face penalties and legal exposure.
• Poor Documentation Practices: Failure to maintain accurate, organized, and complete documentation may lead to sanctions.
• Lack of Training: Employees involved in handling controlled substances must receive adequate training; neglecting this can result in compliance failures during audits.
• Non-compliance with SOPs: Failing to adhere to established SOPs is a common finding that suggests inadequate frameworks and can lead to severe consequences.

Awareness of these common deficiencies aids in proactively addressing weaknesses in compliance and preparing for inspections.

RA-Specific Decision Points

Throughout the regulatory processes associated with controlled substances, various decision points require careful consideration. Some recurring decision issues include:

When to File as Variation vs. New Application

Determining the correct submission type is critical for ensuring regulatory compliance:

• Variation: If the proposed changes are minor and do not significantly alter the dosage, formulation, or added indications of a previously approved product, a variation can be filed.
• New Application: If the changes introduce a new formulation, indication, or a new compound, a new marketing authorization application (MAA) is required.

Justification for your submission route should be clearly documented in submission cover letters to facilitate agency understanding.

How to Justify Bridging Data

Bridging data, which refers to using existing data to support new submissions, can be crucial when dealing with controlled substances:

• Relevance: Ensure the existing data is relevant to the new indication or formulation being proposed. Define how existing data supports the efficacy and safety of the new product.
• Gaps Analysis: Conduct a significant gaps analysis to clearly identify areas where new data may be necessary, while justifying exclusion of certain types of data based on existing knowledge.
• Documentation: Include robust justifications as part of the regulatory submission to minimize potential questions or rejections from agencies.

Conclusion

In summary, standardizing audit risks and legal exposure management across global markets requires an in-depth understanding of regulatory frameworks, effective documentation practices, a clear review and approval process, and pre-emptive decision-making. Regulatory Affairs teams must continuously assess their practices against the backdrop of evolving regulations and agency expectations to assure compliance and mitigate risks. By maintaining rigorous control of documentation, understanding regulatory agency needs, and effectively communicating with stakeholders, successful compliance can be achieved.

For further guidance on regulatory compliance, refer to FDA regulations, or view pertinent documentation from the European Medicines Agency and the MHRA.